Author response for "Efficacy and safety of enavogliflozin, a novel <scp>SGLT2</scp> inhibitor, in Korean people with type 2 diabetes: a 24‐week, multicentre, randomised, double‐blind, placebo‐controlled, phase <scp>III</scp> trial"
crossref（2023）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要